CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
PH12000002657B1
(en)
*
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
KR100660738B1
(ko)
*
|
2000-03-17 |
2006-12-22 |
깃세이 야쿠힌 고교 가부시키가이샤 |
글루코피라노실록시 벤질벤젠 유도체, 그것을 함유하는의약조성물 및 그 제조중간체
|
JP4591781B2
(ja)
*
|
2000-11-02 |
2010-12-01 |
味の素株式会社 |
新規ピラゾール誘導体及びそれらを含有する糖尿病治療薬
|
ATE455785T1
(de)
|
2000-11-02 |
2010-02-15 |
Ajinomoto Kk |
Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
|
EP1344780A4
(en)
*
|
2000-11-30 |
2004-01-28 |
Kissei Pharmaceutical |
GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
|
HU228915B1
(en)
|
2000-12-28 |
2013-06-28 |
Kissei Pharmaceutical |
Glucopyranosyloxypyrazole derivatives and use thereof
|
DE60230591D1
(de)
*
|
2001-02-26 |
2009-02-12 |
Kissei Pharmaceutical |
Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
|
JP4147111B2
(ja)
|
2001-02-27 |
2008-09-10 |
キッセイ薬品工業株式会社 |
グルコピラノシルオキシピラゾール誘導体およびその医薬用途
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
ATE442148T1
(de)
|
2001-04-04 |
2009-09-15 |
Ortho Mcneil Janssen Pharm |
Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
|
JP4590159B2
(ja)
|
2001-04-04 |
2010-12-01 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
グルコース再吸収阻害剤およびpparモジュレーターを含んで成る併用療法
|
AU2002254567B2
(en)
|
2001-04-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
JP4292570B2
(ja)
|
2001-04-27 |
2009-07-08 |
味の素株式会社 |
N−置換ピラゾール−o−グリコシド誘導体及びそれらを含有する糖尿病治療薬
|
CA2448741C
(en)
*
|
2001-05-30 |
2010-06-22 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
|
WO2003000712A1
(fr)
*
|
2001-06-20 |
2003-01-03 |
Kissei Pharmaceutical Co., Ltd. |
Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
|
WO2003011880A1
(fr)
*
|
2001-07-31 |
2003-02-13 |
Kissei Pharmaceutical Co., Ltd. |
Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
|
WO2003020737A1
(en)
*
|
2001-09-05 |
2003-03-13 |
Bristol-Myers Squibb Company |
O-pyrazole glucoside sglt2 inhibitors and method of use
|
JP4424203B2
(ja)
*
|
2002-04-26 |
2010-03-03 |
味の素株式会社 |
糖尿病予防・治療剤
|
US7956041B2
(en)
|
2002-04-26 |
2011-06-07 |
Ajinomoto Co., Inc. |
Prophylactic and therapeutic agent of diabetes mellitus
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
CN100351263C
(zh)
*
|
2002-08-08 |
2007-11-28 |
橘生药品工业株式会社 |
吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
|
MXPA05001549A
(es)
|
2002-08-08 |
2005-05-05 |
Kissei Pharmaceutical |
Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
|
CA2478889A1
(en)
|
2002-08-09 |
2004-02-19 |
Taisho Pharmaceutical Co., Ltd. |
Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
|
JP2004137245A
(ja)
*
|
2002-08-23 |
2004-05-13 |
Kissei Pharmaceut Co Ltd |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
CN100413878C
(zh)
*
|
2002-08-23 |
2008-08-27 |
橘生药品工业株式会社 |
吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
|
WO2004019958A1
(ja)
*
|
2002-08-27 |
2004-03-11 |
Kissei Pharmaceutical Co., Ltd. |
ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
|
AU2003272903A1
(en)
*
|
2002-10-04 |
2004-04-23 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
|
CN1744916A
(zh)
*
|
2002-12-04 |
2006-03-08 |
橘生药品工业株式会社 |
预防和治疗高血糖所导致的疾病
|
DE10258008B4
(de)
*
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
EP1577317A4
(en)
|
2002-12-25 |
2007-05-09 |
Kissei Pharmaceutical |
NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
|
JPWO2004089967A1
(ja)
*
|
2003-04-01 |
2006-07-06 |
大正製薬株式会社 |
ヘテロアリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬
|
CN1761676A
(zh)
|
2003-04-01 |
2006-04-19 |
大正制药株式会社 |
杂芳基5-硫代-β-D-吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药
|
EP1637539B1
(en)
*
|
2003-06-20 |
2012-01-18 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, drug composition containing the same and production intermediate therefor
|
DE502004008951D1
(de)
*
|
2003-08-26 |
2009-03-19 |
Boehringer Ingelheim Pharma |
Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
DE102004028241B4
(de)
|
2004-06-11 |
2007-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
|
JP5010918B2
(ja)
*
|
2004-07-21 |
2012-08-29 |
キッセイ薬品工業株式会社 |
肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
CA2588963C
(en)
|
2004-11-18 |
2013-06-25 |
Kissei Pharmaceutical Co., Ltd. |
1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
EP1864993B1
(en)
*
|
2005-03-17 |
2012-05-16 |
Kissei Pharmaceutical Co., Ltd. |
Process for production of glucopyranosyloxypyrazole derivative
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
UY29694A1
(es)
*
|
2005-07-28 |
2007-02-28 |
Boehringer Ingelheim Int |
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
|
KR100982088B1
(ko)
*
|
2005-08-31 |
2010-09-13 |
에프. 호프만-라 로슈 아게 |
11베타-hsd1 억제제로서의 피라졸론 유도체
|
UY30082A1
(es)
|
2006-01-11 |
2007-08-31 |
Boehringer Ingelheim Int |
Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US20080020987A1
(en)
*
|
2006-07-20 |
2008-01-24 |
Waldemar Pfrengle |
Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
|
JP5330260B2
(ja)
|
2006-12-06 |
2013-10-30 |
スミスクライン ビーチャム コーポレーション |
二環式化合物ならびに抗糖尿病薬としての使用
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
RS52236B
(en)
*
|
2008-08-28 |
2012-10-31 |
Pfizer Inc. |
DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
|
CA2734284C
(en)
*
|
2008-11-20 |
2014-01-21 |
Techno Guard Co., Ltd. |
Pyrazolone derivative formulations
|
WO2010059774A1
(en)
*
|
2008-11-21 |
2010-05-27 |
Glaxosmithkline Llc |
Chemical process
|
CN101445528B
(zh)
*
|
2008-12-25 |
2011-06-15 |
天津药物研究院 |
硫代葡萄糖衍生物、其制备方法和用途
|
JP5600328B2
(ja)
*
|
2009-02-13 |
2014-10-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシルジフェニルメタン誘導体を含む医薬組成物、その医薬剤形、それらの調製方法及び患者の血糖コントロールを改善するためのそれらの使用
|
EP2395983B1
(en)
|
2009-02-13 |
2020-04-08 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
MX2012002942A
(es)
|
2009-09-30 |
2012-04-11 |
Boehringer Ingelheim Int |
Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
|
KR101813025B1
(ko)
|
2009-09-30 |
2017-12-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실치환된 벤질벤젠 유도체의 제조방법
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
US8163704B2
(en)
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
BR112012008924A2
(pt)
|
2009-10-20 |
2019-09-24 |
Novartis Ag |
derivado de glicosídeo e usos do mesmo
|
DK2496583T3
(en)
|
2009-11-02 |
2015-02-02 |
Pfizer |
Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
|
WO2011070592A2
(en)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
EP2697240B1
(en)
|
2011-04-14 |
2015-09-16 |
Novartis AG |
Glycoside derivatives and uses thereof
|
US8614195B2
(en)
|
2011-04-14 |
2013-12-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
MX2013014135A
(es)
|
2011-06-03 |
2014-01-23 |
Boehringer Ingelheim Int |
Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
UA113086C2
(xx)
|
2012-05-10 |
2016-12-12 |
|
Піразольні сполуки як інгібітори sglt1
|
TW201425326A
(zh)
|
2012-10-05 |
2014-07-01 |
Lilly Co Eli |
新穎脲化合物
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
DK2981269T3
(da)
|
2013-04-04 |
2023-10-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Behandling af stofskifteforstyrrelser hos hestedyr
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
HUE041709T2
(hu)
|
2013-04-05 |
2019-05-28 |
Boehringer Ingelheim Int |
Az empagliflozin terápiás alkalmazásai
|
ES2906115T3
(es)
|
2013-04-18 |
2022-04-13 |
Boehringer Ingelheim Int |
Composición farmacéutica, métodos de tratamiento y usos de la misma
|
AR098670A1
(es)
|
2013-11-08 |
2016-06-08 |
Lilly Co Eli |
Inhibidor de sglt1
|
KR20240017116A
(ko)
|
2013-12-17 |
2024-02-06 |
베링거잉겔하임베트메디카게엠베하 |
고양이과 동물에서 대사 장애의 치료
|
ES2951127T3
(es)
|
2014-01-23 |
2023-10-18 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos
|
US10688116B2
(en)
|
2014-04-01 |
2020-06-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
CN104478969A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含烷氧苯基噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104447907A
(zh)
*
|
2015-01-14 |
2015-03-25 |
佛山市赛维斯医药科技有限公司 |
含硝基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104447905A
(zh)
*
|
2015-01-14 |
2015-03-25 |
佛山市赛维斯医药科技有限公司 |
一种含硝基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478956A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478967A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基苯噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478960A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含丙烯腈基和三氟甲苯基o-葡萄糖苷结构化合物和用途
|
CN104497072A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
含丙烯腈和卤代苯o-葡萄糖苷结构衍生物、其制备方法和用途
|
CN104478962A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类卤代苯基s-葡萄糖苷衍生物、其制备方法和用途
|
CN104497073A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
含丙烯腈和烷氧苯基o-葡萄糖苷结构的衍生物和用途
|
CN104497074A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含丙烯腈基和硝基苯o-葡萄糖苷结构化合物及用途
|
AU2017344882A1
(en)
|
2016-10-19 |
2019-03-28 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
|
WO2019201752A1
(en)
|
2018-04-17 |
2019-10-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
US11759474B2
(en)
|
2019-11-28 |
2023-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
CA3167531A1
(en)
|
2020-02-17 |
2021-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
CN117715640A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途
|
KR20240040106A
(ko)
|
2021-07-28 |
2024-03-27 |
베링거잉겔하임베트메디카게엠베하 |
비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
|
WO2023006745A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
WO2023129595A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|